Stratified Medicine and Reimbursement Issues

Stratified Medicine and Reimbursement Issues

Stratified Medicine (SM) has the potential to target patient populations who will most benefit from a therapy while reducing unnecessary health interventions associated with side effects. The link between clinical biomarkers/diagnostics and therapies provides new opportunities for value creation to...

Full description

Bibliographic Details
Main Authors:	Hans-Joerg eFugel, Mark eNuijten, Maarten ePostma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2012-10-01
Series:	Frontiers in Pharmacology
Subjects:	Biomarkers, Pharmacological diagnostics reimbursement Stratified Medicine Health Technology Assessment
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2012.00181/full

Similar Items

Economic evaluation in stratified medicine: methodological issues and challenges
by: Hans-Joerg eFugel, et al.
Published: (2016-05-01)

Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
by: Edward D. Blair, et al.
Published: (2012-11-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
by: Joshua P. Cohen, et al.
Published: (2014-04-01)

Budget impact of publicly reimbursed prescription medicines in The Republic of Srpska
by: Tamara ePetrusic, et al.
Published: (2015-09-01)

Negative Pressure Wound Therapy: Reimbursement situation of this medical device 15 years after entering the European Market
by: Joerg Linder
Published: (2016-04-01)

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

THE ACCESSIBILITY OF PHARMACEUTICALS REIMBURSED FROM THE COMPULSORY HEALTH INSURANCE FUND BUDGET IN TERMS OF PRICES IN 2009−2015
by: Gintarė Petronytė, et al.
Published: (2017-03-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-03-01)

Reimbursement for Emergency Department Electrocardiography and Radiograph Interpretations: What Is It Worth for the Emergency Physician
by: Wu, Tina, et al.
Published: (2009-08-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Financial Consequences of the Act on Reimbursement of Medicines for the National Health Fund and Patients
by: Zofia Skrzypczak, Associate Professor, PhD, et al.
Published: (2019-01-01)

Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement
by: Dong-Sook Kim, et al.
Published: (2021-08-01)

Regularities of Formation of the Labour Reimbursement Institute in the Market Economy
by: Povoroznyuk Inna M.
Published: (2013-11-01)

The History of Reimbursements in Neurology
by: Shaheen E Lakhan, et al.
Published: (2013-11-01)

Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey's Health Care System?
by: Guvenc Kockaya, et al.
Published: (2010-01-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria
by: Georgi Iskrov, et al.
Published: (2016-02-01)

THE AUDIT OF EU NON-REIMBURSABLE FUNDS
by: OCOLIȘANU ANDREEA
Published: (2019-10-01)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
by: Andreja Detiček, et al.
Published: (2018-06-01)

Cost-utility analysis: Current methodological issues and future perspectives
by: Mark J C Nuijten, et al.
Published: (2011-06-01)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
by: Michael Kossmeier, et al.
Published: (2021-08-01)

Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019
by: Mariangela Prada, et al.
Published: (2020-12-01)

Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
by: Mihajlo B Jakovljevic
Published: (2014-03-01)

The effect of insurance reimbursement on services by social workers in private practice
by: Strom, Kimberly Jean
Published: (1993)

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
by: Kyung-Bok Son
Published: (2020-10-01)

The Dilemma of Medical Reimbursement Policy in Rural China: Spatial Variability between Reimbursement Region and Medical Catchment Area
by: Yongqing Dong, et al.
Published: (2019-08-01)

A pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures
by: Thérèse Eriksson, et al.
Published: (2020-08-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Recent developments regarding periostin in bronchial asthma
by: Kenji Izuhara, et al.
Published: (2015-09-01)

Results of reference pricing and reimbursement discount rate schemes of Turkey
by: Guvenc Kockaya, et al.
Published: (2013-03-01)

CONTEMPLATING HEALTH ECONOMICS, CODING AND REIMBURSEMENT IN ORTHOTICS, PROSTHETICS AND PEDORTHICS
by: M. Jason Highsmith, et al.
Published: (2021-09-01)

Reimbursements and frequency of tests in privately insured testicular cancer patients in the United States: Implications to national guidelines
by: Mohamed H Kamel, et al.
Published: (2017-01-01)

Analysing criteria for price and reimbursement of orphan drugs in Spain
by: Xavier Badia, et al.
Published: (2019-07-01)

Health technology assessment and reimbursement of pharmaceuticals in Italy
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

The effects of reimbursement reform of antidiabetic medicines from the patients’ perspective – a survey among patients with type 2 diabetes in Finland
by: Taika Suviranta, et al.
Published: (2019-10-01)

Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases
by: Valentina La Cognata, et al.
Published: (2021-05-01)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
by: Tomas Tesar, et al.
Published: (2019-06-01)

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016
by: A. S. Kolbin, et al.
Published: (2016-04-01)